Armata Pharmaceuticals Highlights AP-SA02 Data at ISSSI 2026
Marina del Rey, California, U.S., September 21, 2026 Armata Pharmaceuticals announced that new data evaluating AP-SA02, its investigational bacteriophage...
antibacterial therapy
Advertisement
Whitehawk Therapeutics’ PTK7 Data Support ADC Development
Waltham, Massachusetts, U.S., September 14, 2026 Whitehawk Therapeutics presented new real-world analyses supporting PTK7 as a durable antibody-drug conjugate...
Bright Path Labs Receives FDA AMT Designation for Medicines
Mesa, Arizona, U.S., September 14, 2026 Bright Path Labs, a U.S.-based pharmaceutical manufacturer, announced that the U.S. Food and...
Armata’s AP-SA02 Receives FDA Breakthrough Designation
Los Angeles, California, U.S., September 14, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
Avere Raises $500M to Advance Weekly Oral IL-23 Therapy
San Francisco, California, USA, August 10, 2026 Avere Therapeutics, Inc. has announced a $500 million private placement from a...
Advertisements
Acurx, Leiden Partner to Advance Novel Antibiotic Discovery
Staten Island, New York, USA, August 10, 2026 Acurx Pharmaceuticals, Inc. has announced a new scientific partnership with Leiden...
Armata Gains FDA Fast Track for AP-SA02 Therapy
LOS ANGELES, May 7, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Advertisement
